Lipella Pharmaceuticals Inc. Common Stock

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company that develops drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for various applications. Its pipeline includes LP-10, a tacrolimus formulation for radiation-induced hemorrhagic cystitis; LP-310, a tacrolimus formulation for oral lichen planus; LP-410, an oral liposomal tacrolimus formulation for oral graft-versus-host disease; and LP-50, an intravesical immunoglobulin formulation for non-muscle invasive bladder cancer. Incorporated in 2005 and headquartered in Pittsburgh, Pennsylvania, the company filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania on March 30, 2026.